VSC

4SC AG, a biopharmaceutical company, engages in developing small-molecule drugs that target key indications in cancer with high unmet medical needs in Germany. The company's product in clinical development stage is Resminostat, an orally administered histone deacetylase inhibitor for the treatment of cutaneous T-cell lymphoma. The company also out-licenses its products to pharma and biotech companies.